Patents by Inventor Gary Gilkeson

Gary Gilkeson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting complement factor H for treatment of diseases
    Patent number: 9212212
    Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: December 15, 2015
    Assignees: The Regents of the University of Colorado, a body corporate, MUSC Foundation for Research Development
    Inventors: Gary Gilkeson, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
  • Inhibition of factor B, the alternative complement pathway and methods related thereto
    Patent number: 8703140
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: April 22, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Gilkeson
  • TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES
    Publication number: 20140073572
    Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
    Type: Application
    Filed: October 1, 2013
    Publication date: March 13, 2014
    Applicants: MUSC Foundation for Research Development, The Regents of the University of Colorado, a Body Corporate
    Inventors: Gary GILKESON, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
  • Targeting complement factor H for treatment of diseases
    Patent number: 8569225
    Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: October 29, 2013
    Assignees: MUSC Foundation for Research Development, The Regents of the University of Colorado, a body corporate
    Inventors: Gary Gilkeson, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
  • TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES
    Publication number: 20110015127
    Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
    Type: Application
    Filed: May 18, 2010
    Publication date: January 20, 2011
    Inventors: Gary GILKESON, Stephen TOMLINSON, V. Michael HOLERS, Baerbel ROHRER
  • Targeting complement factor H for treatment of diseases
    Patent number: 7759304
    Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: July 20, 2010
    Assignees: Regents of the University of Colorado, MUSC Foundation For Research Development
    Inventors: Gary Gilkeson, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
  • Targeting complement factor H for treatment of diseases
    Publication number: 20080221011
    Abstract: The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
    Type: Application
    Filed: June 21, 2007
    Publication date: September 11, 2008
    Inventors: Gary Gilkeson, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
  • INHIBITION OF FACTOR B, THE ALTERNATIVE COMPLEMENT PATHWAY AND METHODS RELATED THERETO
    Publication number: 20080102040
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: August 22, 2007
    Publication date: May 1, 2008
    Inventors: V. Holers, Joshua Thurman, Christian Taube, Erwin Gelfand, Gary Gilkeson
  • Inhibition of factor B, the alternative complement pathway and methods related thereto
    Publication number: 20080075720
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: August 3, 2007
    Publication date: March 27, 2008
    Inventors: Vernon Holers, Joshua Thurman, Christian Taube, Erwin Gelfand, Gary Gilkeson
  • Inhibition of factor B, the alternative complement pathway and methods related thereto
    Publication number: 20050260198
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: February 10, 2005
    Publication date: November 24, 2005
    Applicants: The Regents of the University of Colorado, National Jewish Medical and Research Center, MUSC Foundation for Research Development
    Inventors: Vernon Holers, Joshua Thurman, Christian Taube, Erwin Gelfand, Gary Gilkeson